Home
About
Services
Partners
Client Portfolio
News
Contact
Casino gambles on Amazon-style checkout free Champs Elysees store
October 4, 2018
U.S. plans to rewrite rules that impede self-driving cars
October 4, 2018
0
Lilly’s diabetes drug data impresses, hurts rival Novo’s shares
Published by
Muller&Green
at
October 4, 2018
Categories
RSS
Tags
Eli Lilly and Co said on Thursday its new two-in-one diabetes drug was successful in lowering blood sugar and reducing weight, sending its shares to a record high and weighing on those of arch-rival Novo Nordisk .
Powered by
WPeMatico
Muller&Green
Related posts
June 18, 2020
Chanel warns virus impact will linger on luxury sector
Read more
June 18, 2020
IMF says deeper-than-expected contraction in U.S. economy likely in second quarter
Read more
June 18, 2020
Prudential sells Jackson equity stake to Apollo-backed Athene for $500 million
Read more